Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia

Archives of Internal Medicine

Volumn 159, Issue 20, 1999, Pages 2449-2454

  Ramirez, Julio A ^a,b   Vargas, Sergio ^a   Ritter, Gilbert W ^a   Brier, Michael E ^a   Wright, Allie ^a   Smith, Scott ^a   Newman, David ^a   Burke, John ^a   Mushtaq, Mian ^a   Huang, Anna ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR;

ANTIBIOTIC THERAPY; ARTICLE; ECONOMIC ASPECT; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KENTUCKY; LENGTH OF STAY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DISCHARGE; PATIENT SATISFACTION; PNEUMONIA; PROSPECTIVE STUDIES; RISK; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033536913     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.20.2449     Document Type: Article

References (13)

1. Marston BJ, Plouffe JF, File TM, et al, for the Community-Based Pneumonia Incidence Study Group. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-base active surveillance study in Ohio. Arch Intern Med. 1997;157:1709-1718.
2. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
3. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 1997;157:47-56.
4. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273-1276.
5. Hendrickson J, Norh D. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995;29:561-565.
6. Weingarten SR, Riedinger MS, Hobson P, et al. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med. 1996;153: 1110-1115.
7. Van den Brande P, Vondra V, Vogel F, et al. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest. 1997; 112:406-415.
8. Ramirez JA, Ahkee S. Early switch from intravenous antimicrobials to oral clarithromycin in the treatment of hospitalized patients with community-acquired pneumonia. Infect Med. 1997;14:319-323.
9. Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med. 1995;2:327-333.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
12. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-1457.
13. American Hospital Association Hospital Statistics. Chicago, III: American Hospital Association; 1998:3.